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diabetes treatment for users of this drug. METHODS: Patients were selected from the 
MarketScan® databases who ﬁlled at least one prescription for rosiglitazone during 
the second quarter of 2007 and received at least 90 days of therapy during the ﬁrst 
half of 2007. Each patient’s use of all antidiabetic drugs was tracked by calendar 
quarter during 2007 and 2008. For comparison, similar longitudinal proﬁles were 
constructed for users of pioglitazone (same drug class) and for metformin (different 
class of oral antidiabetic agent). The net impact of the FDA safety warnings on user 
of rosiglitazone was assessed by comparing changes in their antidiabetic drug con-
sumption with those for users of pioglitazone and and metformin. RESULTS: The 
study cohorts included: 37,087 rosiglitazone, 43,607 pioglitazone, and 147,055 met-
formin users. The groups were demographically similar, except for a higher proportion 
of women in the metformin cohort. By the end of 2008 only 32.6% of the rosiglitazone 
cohort continued to ﬁll prescriptions for that agent, compared to 66.5% for piogli-
tazone and 76.5% for metformin. 18.9% of rosiglitazone users switched to piogli-
tazone. They also were more likely than the other cohorts to start using a DPP4 
inhibitor (8.6% v. 6.1% and 5.2%, respectively) or insulin (5.3% v. 4.2% and 4.1%). 
CONCLUSIONS: The safety warnings in 2007 led to a high rate of discontinuation 
of rosiglitazone use, some of which was replaced by pioglitazone and other drugs with 
different mechanisms of action. However, new prescriptions did not fully offset the 
discontinuation of rosiglitazone, so the net result was a reduction in the average 
intensity of therapy.
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OBJECTIVES: Results from a representative German database [1] and ﬁndings from 
a real-life cross-sectional study [2] show an unequal distribution between basal sup-
ported oral therapy (BOT) and intensiﬁed conventional therapy (ICT) regimens in 
type-2-diabetics (T2D) treated with either insulin glargine (GLA) or NPH-insulin 
(NPH). This study assesses whether different persistence on the respective BOT can 
be the reason. METHODS: A Markov model was developed simulating the transition 
from BOT to ICT in the course of ten years in T2D treated either with GLA or NPH. 
Persistence data were obtained from the IMS Disease Analyzer database [3]. The model 
cohort consisted of 44,366 [4,5] statutorily-insured T2D starting a BOT either with 
GLA or NPH at a ratio of 1:1. RESULTS: The number of patients switching from 
BOT to ICT was continually lower in the GLA vs. NPH group (p  0.0002). Therefore, 
the ratio of BOT to ICT in the GLA and NPH group changed differently over time. 
After two years 11,840 patients (from 22,183) remained on BOT in the GLA group 
compared to 6,928 patients (from 22,183) in the NPH group. After 6.50 years all 
patients who have started with a NPH-based BOT switched to ICT. Complete transi-
tion to ICT took 1,75 years longer in the GLA group (8.25 years). The model simula-
tion yield BOT : ICT ratios in the ﬁrst quarter of year 3 for GLA (46%:54%) and for 
NPH (24%:76%), similar to the above mentioned ﬁndings [1;2]. CONCLUSIONS: 
The simulation indicates a correlation between persistence on a basal supported oral 
therapy and the resulting distribution of treatment regimens (BOT : ICT ratio) in T2D 
either treated with GLA or NPH in real-life cross-sectional studies. References: [1] 
ABDA claims data for ambulatory prescriptions, [2] J Med Econ 2008; 11:695–712, 
[3] Diabetologie und Stoffwechsel 2009; 4:1–6 [4] DDU: Gesundheitsbericht Diabetes 
2008 [5] Diabetes und Stoffwechsel 2003; 12:83–94.
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OBJECTIVES: To show the prevalence of DFS and its risk factors in Germany in 
2008. METHODS: Analyses used IMS® Disease Analyzer database (includes repre-
sentative information on approximately 12 million patients from more than 3000 
ofﬁce-based physicians). Patients with a diagnosis of diabetes mellitus in 2008 were 
included. All documented diagnoses of these patients in 2008 based on ICD-10 (inter-
national classiﬁcation of diseases) were analyzed. RESULTS: Data from 116,207 dia- 
betes type-2 patients (T2D) and 9820 (7.8%) diabetes type 1 patients (T1D) were 
analyzed. DFS was registered among 2.6% [2.3–2.9] of T1D patients and 2.1% 
[2.0–2.2] of T2D patients. Projected to national level there are approximately 130,000 
patients diagnosed in 2008. But much more patients had high risk of DFS: 12.0% 
of T1D and 10.5% of T2D patients are discovered among diabetic neuropathy, 
10.9%/12.3% diabetic angiopathy. Additionally 3.6% (T1D) / 9.4% (T2D) were 
diagnosed with foot mycoses and 3.6% (T1D) / 7.0% (T2D) with an open wound 
of foot. The total number of T2D patients with DFS was 2463, mean age 70.9 
[SD: 11.0] years, 1045 (42.4%) women. A total of 553 (22.5%) patients had diabetes 
for 1 year, 1195 (48.5%) for 2–5 years, 547 (22.2%) for 6–10 and 168 (6.8%) 
for more than 10 years. CONCLUSIONS: Results from this analysis of a large repre-
sentative German database show, that even though the prevalence of DFS among 
diabetic patients is relatively low, the prevalence of the main risk factors for DFS 
is much higher. Preventive efforts for avoiding DFS should mainly target these risk 
factors.
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OBJECTIVES: We performed a systematic review and meta-analysis to examine the 
association between HbA1c and the appearance and progression of diabetic retinopathy 
(DR) in T1DM. METHODS: The two electronic medical databases (MEDLINE, 
CENTRAL) were searched to identify all papers reporting HbA1c level and retinopa-
thy in T1DM. Observational and randomized, controlled trials (RCTs) with at least 
one year of follow-up were included. Estimates were made of the adjusted relative risk 
(RR) of complications for an increase in HbA1c of 1%. If available data were insufﬁ-
cient to calculate RR, the odds ratio (OR) was estimated. Weighted mean differences 
(WMD) in HbA1c level between the case group (i.e. with DR) and the control group 
(i.e. without DR) were also calculated. RESULTS: We identiﬁed 16 trials (4176 
patients) that fulﬁlled the inclusion criteria. Based on four RCTs (n  1597), pooled 
RR for progression of DR was calculated as 1.24 (95%CI:1.01–1.52) for an increase 
in HbA1c of 1%. Pooled data from four observational studies (n  910) showed that 
RR of the incidence of DR was 1.59 (CI:1.34–1.89) for HbA1c increase of 1%. A 
meta-analysis of eight observational studies (n  1171) demonstrated a lower HbA1c 
level in patients without DR compared with patients with DR (WMD  0.82 [CI:0.69–
0.96]). In addition, a meta-analysis of ﬁve observational studies revealed that mean 
HbA1c values were signiﬁcantly lower in the group without progression of DR relative 
to the group with DR (WMD  1.05 [CI:0.37–1.72]). One RCT included data on 
visual deterioration and macular oedema; analysis demonstrated that an increase in 
HbA1c level of 1% increased the risk of both macular oedema (RR  1.81 [CI:1.17–
2.81]) and visual deterioration (OR  2.2 [CI:1.2–3.9]). CONCLUSIONS: The results 
of our systematic review indicate a strong correlation between HbA1c level and appear-
ance and progression of DR in T1DM. Thus, HbA1c may be considered an excellent 
surrogate endpoint for DR in T1DM.
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OBJECTIVES: This study uses 5-year population Type II diabetes mellitus data to 
determine the risk of stroke in Taiwan, taking into consideration the age and gender 
of patients, as well as medication pattern. METHODS: The 2,123,104 diabetic 
patients data used are from the Taiwan National Health Insurance Research Database 
covering the period from 1999 to 2004. Newly-diagnosed diabetic patient was deﬁned 
as had 3 or more visits or at least a diabetic code during admission or emergency visit 
in 1999 with a diagnosis of (ICD-9-CM code 250) and who did not have any diabetic 
code in 1998, a total of 681,188 were identiﬁed from the database. 45,949 sample 
patients were identiﬁed from the database by a principal diagnosis of stoke (ICD-9-
CM code 430–438) during next 5 years. The analyses were descriptive in nature, 
including numbers and percentages for the categorical variables. Multiple logistic 
regression was used to compute the relative risk for the associations between different 
medication rate, health service type, physicians, diabetic patients and clinical compli-
cations. RESULTS: We ﬁnd that for the period under examination, there was statistic 
signiﬁcant increase in diabetic stroke incidence with male, age, medication rate, hos-
pital level visit rate, same physician visit rate and bed sore, neuropathy complications. 
CONCLUSIONS: Our ﬁnding of signiﬁcant risk of stroke in diabetic patients of dif-
ferent medication pattern may be explained by severity of disease and important of 
management of diabetic patients.
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OBJECTIVES: To estimate the impact of the of vildagliptin reimbursement within the 
limits of type 2 diabetes mellitus treatment on the budget of the National Health Fund 
in Poland. METHODS: The budget impact analysis was performed with two years 
time horizon, from the public payer’s perspective (National Health Fund) and also 
from both payers’ perspective (National Health Fund and the patient). Polish cost data 
was used (only oral anti-hyperglycemic drugs were considered). Two scenarios were 
compared: present—without reimbursement of vildagliptin, and future—after reim-
bursement of vildagliptin. The prognosis of market vildagliptin shares, sent by the 
Novartis Poland, was used in the analysis. The rate of other oral anti-hyperglycemic 
drugs was estimated on the base of IMS data about the number of units sold in the 
ﬁrst three quarters of the year 2008. Sensitivity analysis was performed to test the 
impact of changes in the assumed parameters of the analysis. RESULTS: Assuming 
the reimbursement of vildagliptin annual expenses from the budget of National Health 
Fund for anti-hyperglycemic drugs would raise by 320.4 thousand PLN (72 thousand 
a) in 2009 and 612.3 thousand PLN (137.7 thousand a) in 2010. Annual expenses 
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from the budget of both payers would raise by 579.5 thousand PLN (130.3 thousand 
a) in 2009 and 1.2 mln PLN (261 thousand a) in 2010. Depending on parameter 
changes, the budget would change by o 17% and o19% for NHS and both payers 
perspective, respectively. CONCLUSIONS: The reimbursement of vildagliptin will 
cause the raise of NHF expenses by 0.37% in 2009 and 0.70% in 2010 of the budget 
spent for oral drugs reimbursed in diabetes mellitus. For both payers’ perspective, the 
reimbursement of vildagliptin will cause the raise expenses by 0.27% in 2009 and 
0.53% in 2010 of the budget.
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OBJECTIVES: To estimate the health care direct costs of an episode of extensive 
superﬁcial or deep uncomplicated foot ulcer of neuropathic origin in patients with 
diabetes in Spain and identify the key factors that inﬂuence total costs. METHODS: 
A retrospective observational study of patients with an episode of foot ulcer during 
the period from January 2007 through December 2008 in 10 Spanish centres was 
performed. Data about sociodemographic characteristics, duration of the episode and       
health care-related resources were considered. The following resources were collected      
from hospital records: inpatient hospitalisations, surgeries, outpatient visits (specialists 
and primary care physician), diagnostic procedures, laboratory tests, ulcer-related 
cures, antibiotics and orthotic devices. Unitary cost (a, year 2009 values) data were 
taken from a Spanish Database of Health Costs and the Catalogue of Medicinal 
Products. RESULTS: Ninety-two patients (29.3% with one or more previous ulcers) 
with a foot ulcer episode were identiﬁed. The majority of cases were males (76.9%).        
Patients’ mean age was 65.20 o 10.90 years and 50.0% of these were retired. Average      
duration of an ulcer episode was 131 o 123 days. Most prevalent comorbidities were 
arterial hypertension (62.0% of cases), diabetic retinopathy (41.3%), renal impair-
ment (30.4%), dyslipidemias (25.0%) and myocardial infarction (19.6%). Concomi-
tant infections during the episode were reported in 33.7% of patients. The average 
cost per patient and ulcer episode was a17,262 (95% conﬁdence interval [CI], 
a11,315, a23,715). The most important categories of costs were for surgeries (a7054, 
95%CI, a6043–a8200, 40.9% of costs), inpatient hospitalisations (a6197, 95%CI, 
a3605–a8878, 35.9% of total costs), and ulcer-related cures (a2864, 95%CI, a1127–
a4759, 16.6% of total costs). Among surgeries, the most relevant were debridements 
and amputations. CONCLUSIONS: An episode of a neuropathic extensive superﬁcial 
or deep uncomplicated diabetic foot ulcer generates a substantial economic burden, 
with a mean cost per patient of a17,262. Surgeries, hospitalisations and ulcer-related 
cures represent 93.4% of total costs.
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OBJECTIVES: Poor glycemic control is associated with increased morbidity and 
mortality among hospitalized patients. Insulin aspart may be more effective in achiev-
ing glycemic control than human insulin. This study compares glycemic control, length 
of stay (LOS), hospital mortality, and charges for hospitalized patients receiving 
insulin aspart or human bolus insulin. METHODS: This study is a retrospective 
analysis of the Health Facts® database (Cerner Corporation, Kansas City, MO). 
Health Facts is a unique database built from hospital comprehensive clinical records 
including pharmacy, laboratory, emergency room, admission, and billing information 
from hospitals throughout the United States, all time-stamped and sequenced. The 
sample included 36,991 medical patients with discharge dates from January 1, 2004 
through December 31, 2007. Patients were segmented into those who exclusively 
received insulin aspart (n  4605, 12.5%) or human (n  32386, 87.6%) bolus insulin. 
Outcomes of interest included blood glucose (BG) control (overall mean BG  140 mg/
dL), length of stay (LOS), in-patient mortality, and hospital charges (in $2007). 
Results were compared with t-tests or chi-square tests. RESULTS: Insulin aspart 
patients demonstrated better blood glucose control (34.22% vs. 30.78% with mean 
BG  140 mg/dL, p  0.001) even though they experienced increased illness as dem-
onstrated by higher Charlson comorbidity scores (2.0 (1.7) vs. 1.9 (1.8), p  0.001) 
and had more heart, kidney, and lung diseases diagnosed during their stay. Insulin 
aspart was also associated with shorter LOS (5.5 (5.4) vs. 6.3 (6.8) p  0.001), lower 
mortality (3.8% vs. 8.7%, p  0.001) and fewer total charges ($25,074 (28,775) vs. 
$33,472 (41704), p  0.001). CONCLUSIONS: Insulin aspart patients appeared to 
have better glycemic control, shorter LOS, lower mortality and reduced hospital 
charges than patients on human bolus insulin. Multivariate adjustments are needed 
to conﬁrm these ﬁndings but the unadjusted results suggest insulin aspart is associated 
with better outcomes than human bolus insulin.
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OBJECTIVES: To estimate treatment costs attributable to overweight or obese status 
in diabetic patients in the U.S.A. METHODS: The data was drawn from the 2003–
2006 Medical Expenditure Panel Survey. Adult patients (18–74 years-old) with dia-
betes were identiﬁed based on a self-reported diagnosis or ICD-9-CM code of 250. 
Patients with pregnancy, malignancy, kidney dialysis, immunodeﬁciency, or body-
mass-index (BMI) 18.5 were excluded. Medical treatment costs included ofﬁce based 
physician/outpatient visits, emergency room visits, or hospitalizations, excluding 
dental problems and injuries. The treatment costs attributable to being overweight 
(25 a BMI  30) or obese (BMI q 30) at various points of the cost distribution were 
estimated using weighted quantile regression after controlling for demographics, 
comorbidities, and other study variables. Treatment costs attributable to being over-
weight/obese were calculated by the differences in the actual treatment costs for over-
weight/obese patients and the expected costs if obese patients were normal-weight 
patients using the study variable coefﬁcients obtained from all patients. All costs were 
converted to 2006 U.S. dollars using price indices. Data were analyzed using SAS and 
SUDAAN. RESULTS: A total of 5338 patients with diabetes were selected for this 
study. Approximately 88% of the diabetic patients were overweight (31%) or obese 
(57%). Compared with normal-weight patients, the incremental treatment costs attrib-
utable to obesity were signiﬁcantly higher by $35, $96, $196, $290, and $739 at the 
10th, 25th, 50th, 75th, and 90th percentiles, respectively. Similar trends were found in 
overweight patients compared with those of normal-weight, but the attributable costs 
were not signiﬁcantly different except at the 75th percentile point. CONCLUSIONS: 
The overall economic burdens attributable to being overweight and obese in diabetic 
patients were substantial and increased signiﬁcantly in the upper tail of the treatment 
cost distribution. The important ﬁnding that the magnitude of attributable costs 
increased across the distribution of treatment costs would not have been possible 
without the quantile regression method.
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OBJECTIVES: The clinical effectiveness of exenatide and glargine is well established 
for the treatment of type 2 diabetes (T2D). However, the relative economic and utiliza-
tion impact of these therapies is uncertain. This study examined the cost offsets associ-
ated with the use of exenatide compared to glargine in patients with T2D. METHODS: 
A retrospective analysis was conducted using a large, managed care claims database. 
Adult patients with T2D who had initiated either exenatide (N  9264) or glargine 
(N  3791) therapy between April 1, 2005 and June 30, 2007 with pre- (6 months) 
and post-index (12 months) continuous eligibility were included. Annual mean total 
medical costs and several mean cost components were estimated using propensity score 
stratiﬁcation to control for baseline demographic, clinical and resource utilization 
variables. Mean costs were estimated using nonparametric bootstrapping. RESULTS: 
Exenatide-treated patients had signiﬁcantly lower total direct medical ($20,792 vs. 
$24,954, p  0.0001), inpatient ($4,836 vs. $6,966, p  0.0001), outpatient ($9,510 
vs. $11,858, p  0.0001), and emergency room (ER) costs ($96 vs. $131, p  0.04). 
Exenatide-treated patients had higher total prescription costs ($6349 vs. $6000, 
p  0.0004). Furthermore, exenatide-treated patients had signiﬁcantly lower costs of 
hospitalization ($4802 vs. $6873, p  .0001) mainly due to lower macrovascular 
complications ($1620 vs. $2661, p  0.001), and also lower ofﬁce visit costs ($3317 
vs. $4176, p  0.0001) and hospital outpatient visits ($5144 vs. $6608, p  0.0001) 
compared to glargine-treated patients. Although prescription costs of exenatide was 
higher than glargine ($1544 vs. $843, p  0.0001), exenatide-treated patients incurred 
signiﬁcantly lower costs of concomitant antidiabetic medications ($1283 vs. $1415, 
p  0.0001) and other prescription medications ($3235 vs. $3438, p  0.015) com-
pared to glargine-treated patients. CONCLUSIONS: Patients who initiated exenatide 
treatment had signiﬁcantly lower total medical costs mainly due to lower inpatient, 
outpatient and ER visits despite having higher total prescription costs. Although, the 
index-drug costs were higher for exenatide, cost savings were observed in hospitaliza-
tions, ofﬁce visits, and hospital outpatient visits.
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OBJECTIVES: To compare the use of opioids and health care costs between patients 
with diabetic peripheral neuropathic pain (DPNP) who initiated treatment with dulox-
etine versus other standard of care DPNP treatments. METHODS: This retrospective 
cohort study analyzed administrative claims database 2004–2006 from a large US 
commercially-insured population to assess opioid utilization and health care costs over 
